Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry
© 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved..
INTRODUCTION AND OBJECTIVES: Coronavirus disease (COVID-19) has been designated a global pandemic by the World Health Organization. It is unclear whether previous treatment with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) affects the prognosis of COVID-19 patients. The aim of this study was to evaluate the clinical implications of previous treatment with ACEI/ARB on the prognosis of patients with COVID-19 infection.
METHODS: Single-center, retrospective, observational cohort study based on all the inhabitants of our health area. Analyses of main outcomes (mortality, heart failure, hospitalization, intensive care unit [ICU] admission, and major acute cardiovascular events [a composite of mortality and heart failure]) were adjusted by multivariate logistic regression and propensity score matching models.
RESULTS: Of the total population, 447 979 inhabitants, 965 patients (0.22%) were diagnosed with COVID-19 infection, and 210 (21.8%) were under ACEI or ARB treatment at the time of diagnosis. Treatment with ACEI/ARB (combined and individually) had no effect on mortality (OR, 0.62; 95%CI, 0.17-2.26; P = .486), heart failure (OR, 1.37; 95%CI, 0.39-4.77; P = .622), hospitalization rate (OR, 0.85; 95%CI, 0.45-1.64; P = .638), ICU admission (OR, 0.87; 95%CI, 0.30-2.50; P = .798), or major acute cardiovascular events (OR, 1.06; 95%CI, 0.39-2.83; P = .915). This neutral effect remained in a subgroup analysis of patients requiring hospitalization.
CONCLUSIONS: Previous treatment with ACEI/ARB in patients with COVID-19 had no effect on mortality, heart failure, requirement for hospitalization, or ICU admission. Withdrawal of ACEI/ARB in patients testing positive for COVID-19 would not be justified, in line with current recommendations of scientific societies and government agencies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Revista espanola de cardiologia - 74(2021), 2 vom: 18. Feb., Seite 175-182 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Impacto de los inhibidores de la enzima de conversión de la angiotensina y los antagonistas del receptor de la angiotensina II en la COVID-19 en una población occidental. Registro CARDIOVID |
|---|
| Beteiligte Personen: |
López-Otero, Diego [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiotensin receptor blockers |
|---|
| Anmerkungen: |
Date Revised 20.04.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.recesp.2020.05.030 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314101055 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314101055 | ||
| 003 | DE-627 | ||
| 005 | 20231225152013.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.1016/j.recesp.2020.05.030 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1046.xml |
| 035 | |a (DE-627)NLM314101055 | ||
| 035 | |a (NLM)32836666 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a López-Otero, Diego |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry |
| 246 | 3 | 3 | |a Impacto de los inhibidores de la enzima de conversión de la angiotensina y los antagonistas del receptor de la angiotensina II en la COVID-19 en una población occidental. Registro CARDIOVID |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a INTRODUCTION AND OBJECTIVES: Coronavirus disease (COVID-19) has been designated a global pandemic by the World Health Organization. It is unclear whether previous treatment with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) affects the prognosis of COVID-19 patients. The aim of this study was to evaluate the clinical implications of previous treatment with ACEI/ARB on the prognosis of patients with COVID-19 infection | ||
| 520 | |a METHODS: Single-center, retrospective, observational cohort study based on all the inhabitants of our health area. Analyses of main outcomes (mortality, heart failure, hospitalization, intensive care unit [ICU] admission, and major acute cardiovascular events [a composite of mortality and heart failure]) were adjusted by multivariate logistic regression and propensity score matching models | ||
| 520 | |a RESULTS: Of the total population, 447 979 inhabitants, 965 patients (0.22%) were diagnosed with COVID-19 infection, and 210 (21.8%) were under ACEI or ARB treatment at the time of diagnosis. Treatment with ACEI/ARB (combined and individually) had no effect on mortality (OR, 0.62; 95%CI, 0.17-2.26; P = .486), heart failure (OR, 1.37; 95%CI, 0.39-4.77; P = .622), hospitalization rate (OR, 0.85; 95%CI, 0.45-1.64; P = .638), ICU admission (OR, 0.87; 95%CI, 0.30-2.50; P = .798), or major acute cardiovascular events (OR, 1.06; 95%CI, 0.39-2.83; P = .915). This neutral effect remained in a subgroup analysis of patients requiring hospitalization | ||
| 520 | |a CONCLUSIONS: Previous treatment with ACEI/ARB in patients with COVID-19 had no effect on mortality, heart failure, requirement for hospitalization, or ICU admission. Withdrawal of ACEI/ARB in patients testing positive for COVID-19 would not be justified, in line with current recommendations of scientific societies and government agencies | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Angiotensin receptor blockers | |
| 650 | 4 | |a Angiotensin-converting enzyme inhibitors | |
| 650 | 4 | |a COVID-19 | |
| 700 | 1 | |a López-Pais, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Cacho-Antonio, Carla Eugenia |e verfasserin |4 aut | |
| 700 | 1 | |a Antúnez-Muiños, Pablo José |e verfasserin |4 aut | |
| 700 | 1 | |a González-Ferrero, Teba |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Poza, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Otero-García, Óscar |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz-Fernández, Brais |e verfasserin |4 aut | |
| 700 | 1 | |a Bastos-Fernández, María |e verfasserin |4 aut | |
| 700 | 1 | |a Bouzas-Cruz, Noelia |e verfasserin |4 aut | |
| 700 | 1 | |a Sanmartín-Pena, Xoan Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Varela-Román, Alfonso |e verfasserin |4 aut | |
| 700 | 1 | |a Portela-Romero, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Valdés-Cuadrado, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Pose-Reino, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a González-Juanatey, José Ramón |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista espanola de cardiologia |d 1961 |g 74(2021), 2 vom: 18. Feb., Seite 175-182 |w (DE-627)NLM000505188 |x 1579-2242 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2021 |g number:2 |g day:18 |g month:02 |g pages:175-182 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.recesp.2020.05.030 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2021 |e 2 |b 18 |c 02 |h 175-182 | ||